BD Reports 1.6% Revenue Growth in Q1 Fiscal 2026

By Chris Stiles • Monday, February 09 12:28 • Permanent Link

BD (Becton, Dickinson and Company) has reported its first-quarter fiscal 2026 financial results, revealing a 1.6% increase in revenue to $5.3 billion. The new BD revenue saw an even stronger increase of 2.5% on a foreign currency neutral basis. The reported diluted earnings per share surged by 28.8% to $1.34, and the adjusted diluted earnings per share dropped by 15.2% to $2.91.

In terms of geographic results, the United States witnessed a 2.6% increase in revenue, while international revenue experienced a marginal 0.2% rise. The company's segment results showed growth in various areas, such as connected care with a 5.5% increase, and BD interventional with a 5.8% rise. However, BD Life Sciences saw a decrease of 8.3% in revenue.

The company has affirmed its fiscal 2026 revenue growth guidance and provided adjusted diluted earnings per share guidance for the new BD. The outlook for the full year fiscal 2026 includes a low single-digit plus revenue growth and adjusted diluted earnings per share in the range of $12.35 to $12.65.

BD is set to complete the combination of its biosciences and diagnostic solutions business with Waters Corporation. The company's CEO, Tom Polen, emphasized that the first-quarter performance reflects their disciplined execution and positions them well to achieve their fiscal 2026 guidance.

BD's recent business highlights include collaborations to expand hazardous drug contamination testing, the implementation of BD Alaris™ EMR infusion interoperability, and investments to support the U.S. pharmaceutical supply chain for biologic drugs.

The company will host an audio webcast to discuss its first-quarter results and provide further insights into its performance and outlook.

BD highlighted that the presentation of results on a foreign currency-neutral basis, in addition to reported results, helps improve investors' ability to understand its operating results and evaluate its performance in comparison to the prior periods. The market has reacted to these announcements by moving the company's shares -0.59% to a price of $207.11. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.